

Low Level Laser Therapy (LLLT) for Neck Pain: A Systematic Review and Meta-Regression

Anita R. Gross^{*1}, Stephanie Dziengo³, Olga Boers³, Charlie H. Goldsmith², Nadine Graham¹, Lothar Lilge⁴, Stephen Burnie³, Roger White⁵ for the Cervical Overview Group[§]

¹McMaster University, Hamilton, Canada

²Simon Fraser University, British Columbia, Canada

³School of Rehabilitation Sciences, Physiotherapy Program, McMaster University, Hamilton, Canada

⁴Department of Medical Biophysics, University of Toronto, Toronto, Canada and Senior Scientist at the Ontario Cancer Institute, Princess Margaret Cancer Centre, UHN, Canada

Theralase Inc., 1945 Queen Street, East Toronto, Ontario M4L 1H7, Canada

Abstract: *Purpose:* This systematic review update evaluated low level laser therapy (LLLT) for adults with neck pain.

Methods: Computerized searches (root up to Feb 2012) included pain, function/disability, quality of life (QoL) and global perceived effect (GPE). GRADE, effect-sizes, heterogeneity and meta-regression were assessed.

Results: Of 17 trials, 10 demonstrated high risk of bias. For chronic neck pain, there was moderate quality evidence (2 trials, 109 participants) supporting LLLT over placebo to improve pain/disability/QoL/GPE up to intermediate-term (IT). For acute radiculopathy, cervical osteoarthritis or acute neck pain, low quality evidence suggested LLLT improves ST pain/function/QoL over a placebo. For chronic myofascial neck pain (5 trials, 188 participants), evidence was conflicting; a meta-regression of heterogeneous trials suggests super-pulsed LLLT increases the chance of a successful pain outcome.

Conclusions: We found diverse evidence using LLLT for neck pain. LLLT may be beneficial for chronic neck pain/function/QoL. Larger long-term dosage trials are needed.

Keywords: Low level laser therapy, neck pain, systematic review.

BACKGROUND

Description of the Condition

Neck pain can be classified as simple "non-specific" neck pain (i.e. sprain/strain) described as pain without specific identifiable etiology and "specific" neck pain with identifiable etiology (i.e. radiculopathy) [1, 2]. According to the Bone and Joint Decade 2000–2010 Task Force, the incidence of neck pain was 150 to 200 per 1000 cases per year, the annual worldwide prevalence varied from 12.1% to 71.5% and neck pain limiting activities was 11.5% [3, 4]. Neck pain is costly to the patient and society. In Quebec, annual prevalence of neck pain in the working population is close to 43% in men and 54% in women [5]. Disabling neck pain is in 10% of men and 18% of women in this population. Over 11% of Ontario workers claimed lost-time benefits due to neck pain [6].

Description of the Intervention

Various treatment strategies including low level laser therapy (LLLT) are used to treat neck pain [6, 7]. The term Laser is an acronym for *light amplification by stimulated emission of radiation*-a form of photonic therapy that is defined by the following characteristics: collimation – it has little beam divergence over distance; convergence – the light waves are all in phase; and monochromaticity – it has a single or narrow band of a particular wavelength of light [8]. Proponents of LLLT note laser devices are either high power or low power. High power laser devices, having a thermal effect, destroy tissue and are used during surgical procedures and for thermolysis. Low power laser devices have little to no thermal effects, have a stimulative effect on target tissues and are used to treat an array of musculoskeletal conditions to decrease pain and inflammation, stimulate collagen metabolism and wound healing, and promote fracture healing [8-10].

Lasers used therapeutically emit relatively low light energy [from a few milliwatts (mW) to 100 to 200 mW] for short periods of time (seconds to minutes) and produces insignificant changes in tissue temperature (measured to be around 1.0 °C). As such, this type of laser is often referred to as LLLT or photomodulation. The wavelength of the light

*Address correspondence to this author at the McMaster University, 1400 Main Street West, Hamilton, Ontario, L8S 1C7, Canada; Tel: 905-525-9149, Ext. 22867; Fax: 905-524-0069; E-mail: grossa@mcmaster.ca

§The Cervical Overview Group is an international research group that conducts and maintains systematic reviews for neck pain.

emitted from lasers varies from >100 to >10000 nanometer (nm) in the electromagnetic spectrum [8] so only wavelength above 193 are transmitted in the atmosphere. Lasers used to stimulate biological tissues were historically produced using a Helium-Neon (HeNe) gas mixture. Light is attenuated exponentially in tissue and the physical penetration depth is given by the distance over which the initial power or energy density dropped to 1/e or ~37% of its original value. The depth over which a sufficient dose can be delivered comprises multiple physical penetration depths and is more commonly quoted in the literature. Here we adopt the clinical usage of this term as the depth to which clinical effects can be achieved. HeNe has a wavelength output of 632.8 nm that is visible red light, is continuous and can penetrate 0.8 mm into tissue with indirect effects of up to 15 mm [8]. Currently low level laser devices are commonly produced from semiconductor diodes composed of crystal compounds such as Gallium-Arsenide (GaAs) or Gallium-Aluminum-Arsenide (GaAlAs), designed to emit laser energy at various specific wavelengths in the infrared range of the electromagnetic spectrum (730nm to 905nm). The infrared (IR)-laser light, GaAs, laser can penetrate up to approximately 5 cm into tissue with a wavelength of 904 nm and is pulsed [8]. The IR-laser, GaAlAs, laser has a wavelength of 830 nm [11, 12], is pulsed, and can penetrate approximately 2 to 3 cm into the tissue [10]. Hence, lasers with longer wavelengths penetrate deeper into the skin tissue than lasers with shorter wavelengths. There is experimental evidence to suggest that the biological effects and physical behaviour of lasers vary with the wavelength of light used [13-15]. The wavelength of red light has been consistently shown to biostimulate cellular responses including membrane permeability, intracellular calcium influx, and ATP production [14-16]. Laser driver technology considers the delivery of the therapeutic dose (J or J/cm²) either with a constant time average or as a pulse light source with low duty cycle but very high dose rate. The pulsed delivery of light allows higher dose-rates to reach deeper tissues, particularly for very short pulsed and low repetition rates. For example, a 905 nm continuous wave infrared laser allows 2.5 cm penetration of a clinically effective dose-rate, while a 905 nm super-pulsed infrared laser allows the same dose-rate even at a 10 cm depth. Super-pulsed infrared laser allows high peak power (50 W) to be delivered in bursts of very short duration (200 nanoseconds). These brief pulses of light energy are delivered at frequencies of up to 10 kHz. Thus superficial tissues will not heat up due to the very short bursts. This (high peak power of short duration and high frequency) allows a therapeutic dose-rate to reach deep tissues. It is however important to note that the dose is not effected by pulsed delivery, only its rate of delivery during the actual emissions cycle of the laser. Dual channel lasers can combine both continuous and pulsed lasers to allow superficial and deep dose-rate delivery of laser energy. Thus laser drive technology allows penetration to deep tissues or more superficial tissue promoting acceleration of healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure tolerance for tissue. Because of the relative ease of producing semiconductor diodes and the relative ability of infrared light to penetrate biological tissues, infrared lasers (GaAs; GaAlAs) are most often used clinically to treat musculoskeletal conditions involving

structures located deep within the joint. Dosage of a laser treatment is calculated using the power output [milliwatts (mW)], the surface area of the laser beam (cm²) and the amount of time the laser beam is in contact with the skin (seconds) [8]. The wavelength of the laser device (nm) determines the quantum energy available for photochemical processes during laser exposure. Laser energy density is measured in joules per square centimeters (J/cm²) of tissue area and laser power emitted is expressed in mW.

How the Intervention Might Work

The degree of biological reaction to decrease pain and inflammation, stimulate collagen metabolism and wound healing and promote fracture healing is believed to depend on a number of factors including power density (W/cm²), the wavelength (nm), the energy density (J/cm²), and site of application [17,18]. The three main mechanisms by which laser produces analgesic effects [19, 20] are believed to be: stimulating endogenous opioid release, elevating pain thresholds [21], and modifying the release of noxious mediators such as bradykinin [22] and histamine [23]. Pain modulation may also occur due to changes in nerve conduction velocity. There have been reports noting that administering laser to nerves resulted in altering the action potential conduction velocity [23] however, several other reports have not demonstrated a clinically important effect of laser on nerve conduction velocity [24, 25]. In addition, there have been some exciting experimental reports which suggest that laser therapy may improve recovery following nerve trauma [26]. Laser therapy has also been found to have an effect on peripheral motor nerve healing [8, 27]. One randomized controlled trial (RCT) assessing HeNe laser on rats with crush injuries found that laser treatment lead to an increased amplitude and velocity of action potentials along the injured motor nerve and an increase in the speed of nerve healing [28]. In summary, LLLT slows down the transmission of pain signals through the autonomic nervous system, regulates serotonin and norepinephrine, and increases the pain threshold [8, 23, 27].

LLLT is also used for inflammation, oedema, swelling, and tissue healing. LLLT application is believed to limit the release of inflammatory mediators, such as bradykinin and histamine, decreasing the inflammatory response [8, 22, 23]. However, it has been strongly hypothesized that a decrease in prostaglandin activity during the inflammatory process is the main anti-inflammatory effect of laser stimulation. Prostaglandins cause vasodilation at the site of inflammation, facilitating infiltration of inflammatory cells to the surrounding tissue. Studies have shown that a decrease in prostaglandin activity due to laser stimulation may promote healing [8, 29].

LLLT stimulate collagen metabolism, wound healing [30], and promotes fracture healing [8-10]. Researchers have also found an increase in collagen and elastic fibers in injured tissue post-laser treatment in animal studies [28]. Similar results were found in other studies [24, 25].

For which clinical outcomes does it work? Laser has been indicated to manage pain associated with many conditions [31] including trigeminal and post-herpetic neuralgia [32, 33], carpal tunnel syndrome [34], fibromyalgia [35], tendonitis [36], osteoarthritis [37], and

rheumatoid arthritis [38]. Little information exists regarding its influence on function.

Why it is Important to Do this Review

Fourteen reviews published between 2005 and 2011 included LLLT either as the main intervention, as the comparator treatment or as part of a multi-modal intervention had a low AMSTAR ratings ranging from 4 to 8 of a possible 11 total score. Three were of higher quality (AMSTAR > 6) (Gross 2007 [39]– 8, Leaver 2010 [40] – 7, Chow 2009 [41] – 8). There are conflicting reports from these reviews. Our previous review found evidence to support the use of LLLT for pain reduction and functional improvement in the intermediate term for acute/subacute and chronic mechanical neck disorder (MND)/degenerative changes [39, 41]. Leaver *et al.* show unclear evidence for the effectiveness of LLLT compared to control groups [40,41]. A systematic review of 16 RCTs showed that LLLT reduces pain from immediate post-treatment in acute neck pain and up to 22 weeks following completion of treatment in those with chronic neck pain [41]. However, the clinical heterogeneity of the pooled trials in this review by Chow and colleagues was debated due to varied dosage [41]. In our current update, we utilized a meta-regression to explore this latter issue and categorized findings by specific subgroups to enhance clinical applicability and generalizability.

Objective

This systematic review update assessed the effect of LLLT on pain, function, patient satisfaction, quality of life, and global perceived effect in adults suffering from mechanical neck pain with or without cervicogenic headache or radiculopathy. Where appropriate, the influence of risk of bias, duration of the disorder and subtypes of neck disorder on the treatment effect was assessed. A meta-regression explored key dosage factors set a priori.

METHODS

Criteria for Considering Studies for this Review

Our criteria and methodology were consistent with our published protocol for our Cochrane reviews {Langevin P, 2011 3823 /id;Gross AR, 2010 3822 /id} and followed the Cochrane Handbook {Higgins, 2008 3825 /id} or PRISMA Guidelines [45]. A protocol specific to this review was not published or registered.

Types of Studies

We included any published and unpublished RCTs in any language.

Types of Participants

The subjects of included studies were adults (18 years of age or older) with acute (less than 30 days), sub-acute (30 to 90 days) or chronic (longer than 90 days) neck pain categorized as simple non-specific mechanical neck pain including sprains and strains {Tsakitzidis G, 2009 3816 /id}, neck pain associated with myofascial pain syndrome (MPS) and degenerative changes [47], cervicogenic headache [48], whiplash [49, 50], and radiculopathy [48].

We excluded studies that addressed neck disorders with definite or possible long tract (upper motor neuron) signs;

with neck pain caused by other pathological entities (i.e. systemic diseases, infections, fractures or grade IV neck pain); with headache not of cervical origin, but associated with the neck (i.e. migraine, tension-type headache) [48].

Types of Interventions

Studies using LLLT alone or in combination with other interventions were included. Acceptable comparison groups were placebo, another intervention (i.e. exercise), or other treatment added to both arms of the trial (i.e. LLLT plus exercise versus sham LLLT plus exercise). The comparisons were arranged in the results first by control intervention and then by comparison intervention for disorder subtypes.

Types of Outcome Measures

The outcomes of primary interest were pain intensity, function, and disability. Quality of life, global perceived effect and patient satisfaction were also investigated. Periods of follow-up were immediately post treatment (about one day); short-term (closest to three months); intermediate-term (closest to 6 months); and long-term (closest to 12 months).

Search Methods for Identification of Studies

We screened citation titles and abstracts using pre-piloted forms and two independent authors. We did an updated search for the following computerized databases, without language restrictions from 2006 up to Feb 2012: MEDLINE, EMBASE, Manual Alternative and Natural Therapy, Cumulative Index to Nursing and Allied Health Literature, Index to Chiropractic Literature, and CENTRAL (Cochrane Library Issue 2, 2010) (See Appendix 1 for MEDLINE search). We included the following MeSH headings and key words for physical medicine methods: phototherapy, lasers, physical therapy, combined modality therapy, exercise, exercise therapy, rehabilitation, low level laser therapy, and neck pain. We also screened reference lists, identified content experts and searched select conference proceedings for grey literature.

Data Collection and Analysis

Standard mean difference (SMD) and relative risks (RR) with 95% confidence intervals (CI) were calculated using a random effects model. For continuous outcomes reported as medians, we calculated effect sizes based on Kendall [(p 237)] [51]. In addition, we calculated number needed to treat (NNT) and the percent treatment advantage for pain; this is the difference between the changes in the treatment and control groups divided by their respective baselines.

Selection of Studies

Two independent reviewers selected articles for inclusion and data extraction; quadratic weighted kappa (K_w) [52] was used to assess agreement. Disagreement was resolved through discussion. Study authors were contacted for clarification when needed. Selection of articles in languages other than English was performed with the assistance of a translator with a medical, science or research background.

Assessment of Risk of Bias

The Cervical Overview Group used a team of assessors with at least two assessors who independently assessed each study using the 12 criteria for risk of bias (Fig. 4). The

quadratic weighted Kappa (K_w) statistic was used to assess agreement on risk of bias assessment (K_w 0.23 to 1.00). Risk of bias was discussed by the broader validity assessment team to maximize inter-rater reliability. {Graham, 2012 3832 /id} A low risk of bias is defined as meeting six or more criteria.

Measures of Treatment Effect

For the purpose of this review, we utilized a 10-point change on a 100-point pain intensity scale [small: weighted mean difference (WMD) < 10%; moderate: 10% ≤ WMD < 20%; large: 20% ≤ WMD of the VAS scale] to be a minimal clinically important difference between treatments. Additionally, we considered a difference of five neck disability index units (10%) to be the minimal clinically important difference for the neck disability index [54]. In the absence of clear guidelines on the size of a clinically important effect size [measured as Standard Mean Difference (SMD)], we used a commonly applied system by Cohen; small (0.20), medium (0.50) and large (0.80) [55].

Assessment of Heterogeneity

Before calculating a pooled effect measure, we assessed the reasonableness of pooling on clinical and biological

grounds and assessed statistical heterogeneity (Cochrane Q, $p < 0.01$; $I^2 > 0.40$).

Data Synthesis

Two of our reviewers independently examined the quality of the evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria recommended by Cochrane Collaboration. {Furlan, 2009 1433 /id; Higgins, 2008 3825 /id} Domains considered in this assessment were: 1) the study design, 2) risk of bias, 3) consistency of results, 4) directness (generalizability), 5) precision (sufficient data), and 6) other considerations (i.e. publication bias). The studies were classified according to standardized published grade criteria (See Table 1). {Altan, 2005 3836 /id}

Subgroup Analysis

Data are presented by categories of disorder subtype and duration of disorder. Subgroup analysis was explored using the funnel plot when data were available (Fig. 1).

Sensitivity Analysis

Sensitivity analyses and meta-regression were planned for variables identified a priori: methodological quality,




Fig. (1). Funnel plot for subgroup analysis.

Table 1. The Quality of Evidence Utilizing the GRADE Approach are Defined

| GRADE | Definition |
|----------|--|
| High | Further research is very unlikely to change our confidence in the estimate of effect (all of the domains are met). |
| Moderate | Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate (one of the domains is not met). |
| Low | Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate (two of the domains are not met). |
| Very Low | We are very uncertain about the estimate (three or more of the domains are not met). |

subtype disorder, duration of symptoms, and dosage. One role of meta-regression is to explain the heterogeneity in terms of study-level covariates. Variables with a significance level < 0.10 were retained as potential prediction factors. The significance level was selected to increase the likelihood that no potential prediction variable would be overlooked. Four dosage variables were identified by team consensus [two physiotherapists (1 PhD, 1 clinician), a chiropractor (clinician), a physicist (PhD), an engineer] a priori as being of greater clinical relevance [energy density (J/cm²), dosage per session (J), dosage per treatment program (J) and drive technology (applied technology of delivering the energy of the lasers – pulsed vs continuous)], and were entered into the regression model to determine the best set of variables to predict treatment success. It is important to note that if drive technology is a confounding factor that the total density as well as the power density (or the rate of delivering the ‘dose’) are outcome determining parameters. The MCID for pain was used to define treatment success. These variables were abstracted and reported for each trial in Table 3 – Laser Dosage and Clinical Characteristics.

Clinical Applicability

Two reviewers independently assessed all articles with a clinical applicability checklist (agreement varied from 83 to 100%; Fig. 2).

RESULTS

Results of the Search

For this update, we selected 17 studies from 110 citation postings related to laser from 2171 identified citations for physical medicine methods search strategy [K_w0.85 (95%CI: 0.69 to 1.00)] (Fig. 3).

Description of Included Studies

Eleven trials examined chronic MPS {Thorsen, 1991 3810 /id;Thorsen, 1992 205 /id;Altan, 2005 3836 /id;Ceccherelli, 2006 2751 /id;Chow R, 2004 3851 /id;Dundar, 2007 2816 /id;Gur, 2004 3838 /id;Hakguder, 2003 3840 /id;Ilbuldu, 2004 3842 /id;Seidel U, 2002 3844 /id;Waylonis G, 1988 3846 /id}; one chronic [66] or one acute neck pain [67]; one chronic cervicogenic headache

[68], four cervical osteoarthritis [67, 9-71] and one acute radiculopathy [72].

Risk of Bias in Included Studies

Seven of the 17 included studies were rated low risk of bias (Table 2) [11, 59, 62, 64, 66, 69, 72]. The primary methodological weaknesses were a failure to report participant compliance, to adequately describe the randomization procedure, to detail allocation concealment and to carry out intention-to-treat analysis (see Fig. 4). We assessed selective outcome reporting as being consistently unclear. Funnel plot analysis suggests a publication bias in which small, negative trials are not published (Fig. 1).

LLLT (HeNe 632.8 nm) Versus Placebo

Low quality evidence (1 trial, 55 participants) showed no benefit for chronic MPS in pain reduction or analgesic intake immediately post-treatment [65].

LLLT (HeNe 632.8 nm) + Exercise Versus Comparison + Exercise

Very low quality evidence (1 trial, 40 participants) that compared LLLT plus exercise to either exercise plus dry needling or exercise plus sham laser in patients with chronic MPS, showed significant improvements in pain intensity and physical activity immediately after treatment but did not maintain at six-month follow-up [63].

LLLT (830 nm or 904 nm) Versus Placebo

Eleven placebo-controlled trials evaluated LLLT in chronic MPS [11,12, 61, 64, 69] cervical osteoarthritis (OA) [69-71], acute neck pain with or without associated OA [67], acute radiculopathy [72] and chronic neck pain [59, 66]. The trials were statistically not homogenous (p < 0.00001); two trials favored placebo [11, 12], another found no difference [64] and eight trials [59, 61, 66, 67, 69-72] favored treatment. These trials were not clinically homogenous. Meta-regression was not feasible due to the small number of trials per factor. While sensitivity analysis of two factors (the duration of the disorder and methodological quality) appeared not to influence our findings, the disorder subtype did as follows (see Fig. 5):




Fig. (2). Clinical applicability across all LLLT trials for neck pain.




Fig. (3). PRISMA flow diagram for study selection.




Fig. (4). The risk of bias for all LLLT trials is depicted by each criterion.

Table 2. Methodological Quality and Outcome for Each Trial

| Author/Year Participants (nA/nR) | Intervention | Methodological Quality | | | | | | | | | | | | | | Main Outcomes |
|---|------------------------|------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|--|
| | | A | B | C | D | E | F | G | H | I | J | K | L | M | T | |
| Altan 2005 {Altan, 2005 3836 /id} Chronic myofascial pain syndrome 48/53 | LLLT-904 nm vs placebo | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 4 | <p><i>PAIN INTENSITY (VAS 0-10)</i> Baseline Mean: group 1 6.85, group 2 6.24 End of Study Mean: group 1 3.17, group 2 3.80 Absolute Benefit: group 1 3.68, group 2 2.44 Reported Results: no significant difference SMD: -1.14 (95% CI: -1.75, -0.52) <i>SIDE EFFECTS: NR</i></p> |
| Ceccherelli 1989[69] Chronic myofascial pain syndrome with degenerative changes 27/27 | LLLT-904 nm vs placebo | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 7 | <p><i>PAIN INTENSITY(Scott-Huskisson test, VAS 0-100)</i> Baseline Mean: group A 46.69, group B 29.21 End of Study Mean: group A 8.46, group B 35.57 Absolute Benefit: group A 38.23, group B -6.36 Reported Results: significant difference favouring laser SMD at 4w Rx: -1.80 (95% CI: -2.64, -0.83) SMD at 4w Rx + 12w f-u: -1.74 (95%CI: -2.64, -0.83) NNT: 2; Treatment Advantage: 71% <i>SIDE EFFECTS: NR</i></p> |
| Chow 2004 [59] Myofascial pain syndrome 19/20 | LLLT-830 nm vs placebo | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 9 | <p><i>PAIN INTENSITY (VAS 0-10)</i> Baseline Mean: group A 3.9, placebo 3.2 Mean difference at 12 weeks: group A -2.1, placebo -0.7 Reported results: not significant, p=0.210 Percentage improvement (baseline to 12 weeks): group A 11.02%, placebo 10.49%, p < 0.039 SMD at 7w Rx + 4w f-u: -5.70 (-7.92, -3.47) NNT: 4; Treatment Advantage: 32% <i>QUALITY OF LIFE (SF-36, PCS)</i> Baseline Mean: group A 39.0, placebo 41.4 Mean difference at 12 weeks: group A 4.0, placebo 1.22 Reported results: not significant, p=0.4 SMD at 7w Rx + 4w f-u: -6.62 (-9.15, -4.09) <i>FUNCTION (NPNPQ)</i> Baseline Mean: group A 0.37, placebo 0.3 Mean difference at 12 weeks: group A -0.12, placebo -0.007 Reported results: significant, p < 0.023 SMD at 7w Rx + 4w f-u: -10.79 (-14.75, -6.84) NNT: 8; Treatment Advantage: 30.1% <i>Self-reported improvement</i> Difference between baseline and 12 weeks: group A 66.7%, placebo 16.6%, p < 0.001 SMD at 7w Rx + 4w f-u: -16.98 (-23.11, -0.85) <i>SIDE EFFECTS</i> Unusual tiredness (number NR)</p> |
| Chow 2006 [66] Chronic cervical pain 90/90 | LLLT-830 nm vs placebo | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 9 | <p><i>PAIN INTENSITY (VAS 0-10)</i> Baseline Mean: group A 5.9, placebo 4.0 End of Study Mean: group A 3.2, placebo 3.7 Absolute Benefit: group A -2.7, placebo -0.3 Reported Results: significant improvement favouring laser SMD: -2.02 (95% CI: -2.54, -1.51) NNT: 2; Treatment Advantage: 53% <i>FUNCTION (NPNPQ)</i> Baseline Mean: NR End of Study Mean: NR Absolute Benefit: group A 3.5, placebo 0.6 Reported Results: significant improvement favouring laser SMD: -0.59 (95%CI Random: -1.02, -0.17) NNT*; Treatment Advantage* <i>GLOBAL PERCEIVED EFFECT (SAI%)</i></p> |

(Table 2) contd.....

| Author/Year Participants (nA/nR) | Intervention | Methodological Quality | | | | | | | | | | | | | | Main Outcomes |
|---|--|------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | A | B | C | D | E | F | G | H | I | J | K | L | M | T | |
| Chow 2006 [66] Chronic cervical pain 90/90 | LLLT-830 nm vs placebo | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 9 | Baseline Mean: NR End of Study Mean: NR Absolute Benefit: group A 43.8, placebo 2.1 Reported Results: significant improvement favouring laser SMD: -1.52 (95% CI Random: -1.99, -1.05) NNT*; Treatment Advantage* <i>QUALITY OF LIFE (SF-36 PCS)</i> Baseline Mean: NR End of Study Mean: NR Absolute Benefit: group A 3.2, placebo -1.3 Reported Results: significant improvement favouring laser SMD: -0.50 (95% CI Random: -0.92, -0.08) NNT*; Treatment Advantage* <i>SIDE EFFECTS</i> : increased stiffness in treatment group |
| Dundar 2007 [60] Chronic myofascial pain syndrome 64/64 | LLLT-830 nm vs placebo | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 6 | <i>PAIN INTENSITY (VAS 0-10)</i> Baseline Mean: Group 1 4.1, group 2 4.2 End of Study Mean: group 1 3.2, group 2 3.2 Absolute Benefit: group 1 0.9, group 2 1.0 Reported Results: no significant difference SMD: 0.00 (95% CI Random: -0.49, -0.49) <i>FUNCTION (NDI 0-50)</i> Baseline Mean: group 1 29.4, group 2 30.8 End of Study Mean: group 1 18.8, group 2 23.7 Absolute Benefit: group 1 10.6, group 2 7.1 Reported Results: no significant difference SMD: -0.41 (95% CI Random: -0.90, 0.09) <i>SIDE EFFECTS</i> : Not observed |
| Gur 2004 [61] Chronic myofascial pain syndrome 54/60 | LLLT-904 nm vs placebo | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 6 | <i>PAIN INTENSITY (VAS 0-10)</i> Baseline Mean: group A 7.39, placebo 6.87 End of Study Mean: group A: 4.28, placebo 1.08 Absolute Benefit: group A: 3.11, placebo 5.79 Reported Results: significant improvement favouring laser SMD at 2w Rx: -0.97 (95% CI Random: -1.54, -0.41) SMD at 2w Rx + 10w f-u: -0.67 (95% CI Random: -1.22, -0.12) NNT: 3; Treatment Advantage 35% <i>FUNCTION (NPDS)</i> Baseline Mean: group A 65.36, placebo 68.52 End of Study Mean: group A: 26.91, placebo 6.65 Absolute Benefit: group A: 38.45, placebo 61.87 Reported Results: significant improvement favouring laser SMD at 2w Rx + 10w f-u: -0.82 (95% CI Random: -1.38, -0.26) NNT: 4; Treatment Advantage: 29% <i>QUALITY OF LIFE (NHP)</i> Baseline Mean: group A 78.92, placebo 69.61 End of Study Mean: group A: 37.44, placebo 0.00 Absolute Benefit: group A: 41.48, placebo 69.61 Reported Results: significant improvement favouring laser SMD at 2w Rx + 10w f-u: -0.58 (95% CI Random: -1.13, -0.04) NNT: 3; Treatment Advantage: 28.6 <i>SIDE EFFECTS</i> : Tiredness in one patient |
| Hakguder 2003 [62] Myofascial pain syndrome Duration NR 62/62 | LLLT 780 nm + stretching exercise vs muscle specific exercise program | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 8 | <i>PAIN INTENSITY (VAS 0-10)</i> Baseline Mean: LLLT 7.54, control 7.03 End of Study Mean: 3 weeks f-u, LLLT 3.06, control 5.19 Absolute Benefit: LLLT 4.48, control 1.84 SMD -1.24 (95% CI -1.78, -0.69), p < 0.001 NNT 4; Treatment Advantage 33% <i>SIDE EFFECTS</i> : NR |

(Table 2) contd.....

| Author/Year Participants (nA/nR) | Intervention | Methodological Quality | | | | | | | | | | | | | | Main Outcomes |
|---|---|------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|--|
| | | A | B | C | D | E | F | G | H | I | J | K | L | M | T | |
| Ilbuldu 2004 [63] Chronic myofascial pain syndrome NR/60 | LLLT-632.8 nm vs dry needling vs placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | <p><i>PAIN INTENSITY(VAS-activity 0-10)</i> Baseline Mean: laser 5.5, placebo 5.7, dn 5.1 End of Study Mean: laser 2.1, placebo 3.7, dn 3.7 Absolute Benefit: laser 3.4 placebo 2.0, dn 1.4 Reported Results: significant difference favours laser SMD (laser v pl): -0.89 (95%CI Random: -1.55, -0.24) SMD (laser v dn): -0.84 (95%CI Random: -1.49, -0.19)</p> <p><i>PHYSICAL ACTIVITY (0-100)</i> Baseline Mean: laser 59.54, placebo 60.42, dn 70.01 End of Study Mean: laser 13.51, placebo 32.16, dn 33.86 Absolute Benefit: laser 41.03, placebo 28.26, dn 36.15 Reported Results: significant difference favours laser SMD (laser v pl): -0.58 (95%CI Random: -1.22, 0.05) SMD (laser v dn): -0.71 (95%CI Random: -1.35, -0.07) NNT*</p> <p><i>SIDE EFFECTS: NR</i></p> |
| Konstantinovic 2010 [72] Acute neck pain with radiculopathy 60/60 | LLLT- 905 nm vs. placebo | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 9 | <p><i>PAIN INTENSITY(0-100)</i> <i>Neck Pain:</i> Baseline Mean: group A 56.84, placebo 58.45 Post-treatment Mean: group A 33.35, placebo 39.45 Reported results: not significant, p=0.077 SMD -0.60 (-1.14, -0.06) NNT: 17; Treatment Advantage: 8.8%</p> <p><i>FUNCTION (NDI 0-100%)</i> Baseline Mean: group A 67.65, placebo 66.87 Post-treatment Mean: group A 37.81, placebo 41.74 Reported results: significant, p=0.01 SMD -0.68 (-1.22, -0.14) Treatment Advantage: 6.5%</p> <p><i>QUALITY OF LIFE (SF-12)</i> Baseline Mean: group A 11.09, placebo 11.03 Post-treatment Mean: group A -16.09, placebo -15.13 Reported results: significant, p=0.002 SMD -0.71 (95% CI -1.25, -0.16) Treatment Advantage: 8.0%</p> <p><i>SIDE EFFECTS:</i> Worsening of pain (6/30) Persistent nausea (1/30) Increase in blood pressure (1/30)</p> |
| Nilsson 1995 [68] Chronic neck disorder with cervicogenic headache 38/40 | LLLT (WL NR) & massage vs manipulation | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 5 | <p><i>HEADACHES INTENSITY(VAS 0-100)</i> Baseline Median: laser 37, manipulation 48 End of Study Median: laser 6, manipulation 15 Absolute Benefit: laser 31, manipulation 33 Reported Results: significant difference favours manipulation group SMD at 3w Rx + 1w f-u: 0.63 (0.08, 1.19) <i>SIDE EFFECTS: NR</i></p> |

(Table 2) contd.....

| Author/Year Participants (nA/nR) | Intervention | Methodological Quality | | | | | | | | | | | | | | Main Outcomes |
|---|---|------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|--|
| | | A | B | C | D | E | F | G | H | I | J | K | L | M | T | |
| Özdemir 2001 [70] Cervical osteoarthritis Duration NR 60/60 | LLLT-830 nm vs placebo | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 5 | <p><i>PAIN INTENSITY(VAS 0-10)</i> Baseline Mean: laser 7.7, placebo 7.3 End of Study Mean: laser 2.4, placebo 6.8 Absolute Benefit: laser 5.3, placebo 0.5 Reported Results: significant difference favours laser SMD: -3.86 (95%CI Random: -4.73, -2.98) NNT: 2; Treatment Advantage: 63%</p> <p><i>FUNCTION (NPDS)</i> Baseline Mean: laser 82.6, placebo 81.6 End of Study Mean: laser 24.5, placebo 74.8 Absolute Benefit: laser 68.1, placebo 6.8 Reported Results: significant difference favours laser SMD: -4.51 (95%CI Random: -5.48, -3.53) NNT: 2; Treatment Advantage: 62%</p> <p><i>SIDE EFFECTS: NR</i></p> |
| Seidel 2002 [64] Chronic mechanical neck disorder (tendomyosis) 48/51 | LLLT-830 nm vs placebo; LLLT-830 nm vs acupuncture; (Dosed: LLLT-30 mW LLLT-7 mW) | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 8 | <p><i>PAIN (VAS 0-100)</i> Baseline Mean: 7 mW 37.7, 30 mW 35.1, Acup 39.3, Pl 34.1 End of Study Mean: 7 mW 17.7, 30 mW 25.2, Acup 9.4, Pl 19.6 Absolute benefit: 7 mW 20.0, 30 mW 9.9, Acup 29.9, Pl 14.5 Reported Results: no significant difference at 4w follow-up LLLT vs Pl, significant difference favouring Acupuncture for LLLT vs Acupuncture SMD (LLLT-7 mW vs Pl) -0.29(95%CI: -1.10, 0.51) SMD (LLLT-30 mW vs Pl) 0.83(95%CI:-0.01, 1.67) SMD (LLLT-7 mW vs Acup) 1.53(95%CI: 0.60, 2.46) SMD (LLLT-30 mW vs Acup) 2.77(95%CI:1.60,3.94) <i>SIDE EFFECTS: none</i></p> |
| Soriano 1996 [67] Acute cervical pain with or without arthrosis 71/79 | LLLT-904 nm vs placebo | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 6 | <p><i>PAIN RELIEF (cut point = excellent vs other)</i> Baseline Mean: A 9.35, B 9.09 End of study Mean: NR Reported Results: significant favouring LLLT RR 0.39 [95%CI Random: 0.24, 0.64] NNT 3; Treatment Advantage: 50%</p> <p><i>RECURRENCE OF PAIN (NOTE: 34% lost to follow-up)</i> Reported Results: significant favouring LLLT (14%) vs Placebo (58%) RR 0.24 [95%CI Random: 0.10, 0.63]§ <i>SIDE EFFECTS: none</i></p> |
| Taverna 1990 [71] Cervical osteoarthritis Duration NR 38/40 | LLLT-830 nm vs placebo | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | <p><i>PAIN and FUNCTION (Combined pain and Karnofsky Function Scale)</i> Baseline: NR Reported Results: significant difference favours laser RR 0.30 (95%CI Random: 0.12, 0.76) NNT: 3; Treatment Advantage: 47%</p> <p><i>SIDE EFFECTS: NR</i></p> |
| Thorsen 1991 [11] Chronic myofascial pain 36/39 | LLLT-830 nm vs placebo | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 7 | <p><i>PAIN INTENSITY(VAS-rest 0-10)</i> Baseline Median: laser 10.4, placebo 8.4, End of Study Median: laser 11.4, placebo 7.2 Absolute Benefit: laser -1.4, placebo 1.2 Reported Results: no significant difference Median effect size: SMD 0.72 (95%CI Random: 0.04, 1.40) <i>SIDE EFFECTS: none</i></p> |

(Table 2) contd.....

| Author/Year Participants (nA/nR) | Intervention | Methodological Quality | | | | | | | | | | | | | | Main Outcomes |
|--|--------------------------|------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|--|
| | | A | B | C | D | E | F | G | H | I | J | K | L | M | T | |
| Thorsen 1992 [12] Chronic myofascial pain 47/52 | LLLT-830 nm vs placebo | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 5 | PAIN INTENSITY(VAS-rest 0-10) Baseline Median: laser 1.90, placebo median 1.10 End of Study Median: laser 1.75, placebo 0.80 Absolute Benefit: laser 0.15, placebo 0.30 Reported Results: significant difference favoured placebo Median effect size: SMD 0.89 (95% CI Random: 0.29, 1.49) SIDE EFFECTS: nausea, symptom aggravation |
| Waylonis 1988 [65] Chronic myofascial pain 55/62 | LLLT-632.8 nm vs Placebo | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 4 | PAIN (MPQ) Baseline Means: NR Reported Results: not significant, composite data for the groups p value 0.5591, ANOVA by repeated measures: between groups F (12, 204) = 0.889 SIDE EFFECTS: placebo group 2 people had increased pain; laser group 2 people had numbness and tingling; 1 person had a temporary skin rash |

Note: Cochrane criteria for risk of bias. (Score 1 if Yes) A. Was the method of randomization adequate?; B. Was the treatment allocation concealed?; C. Was the patient blinded to the intervention?; D. Was the care provider blinded to the intervention?; E. Was the outcome assessor blinded to the intervention?; F. Was the drop-out rate described and acceptable?; G. Were all randomized participants analyzed in the group to which they were allocated?; H. Are the reports of the study free of suggestion of selective outcome reporting?; I. Were the groups similar at baseline regarding the most important prognostic indicators?; J. Were co-interventions avoided or similar?; K. Was the compliance acceptable in all groups?; L. Was the timing of the outcome assessment similar in all groups?; M. Was the study apparently free of other problems that could put it at a risk of bias?

* Unable to calculate.

§ Wrote author for raw data: no response received to date.

Key: MND mechanical neck disorder; NDH neck disorder with headache; LLLT low level laser therapy; n number, nA/nR sample number analyzed/randomized; VAS visual analogue scale; SMD standard mean difference; WMD weighted mean difference; CI confidence interval; NNT number needed to treat; NR not reported; NPNPQ Northwick Park Neck Pain Questionnaire; SAI% Self-Assessed Global Improvement; NPDS Neck Pain and Disability Visual Analog Scale; NHP Nottingham Health Profile, vs versus, nm nanometres, MPS myofascial pain syndrome, pl placebo, acup acupuncture, Rx treatment, w weeks, f-u follow-up, PCS physical component summary, mWmilliwatt, mm millimetres, OA osteoarthritis, RR relative risk, ANOVA analysis of variance, T total Cochrane methodological quality score, NDI Neck Disability Index, dn dry needling, SF-36 short-form 36, SF-12 short form 12.

Disorder Subtype 1 - Cervical Osteoarthritis

Four trials studying neck pain associated with osteoarthritis/arthrosis showed positive results for pain and function [67, 69-71]. First, when we performed the test for heterogeneity for the two trials assessing participants with osteoarthritic changes that reported continuous outcomes [69,70], they were heterogenous ($p = 0.001, I^2 = 94.9\%$). Both trials showed evidence of benefit, but we did not pool them. This difference may relate to variations in treatment characteristics and dosage; however, formal assessment needs to be conducted through meta-regression when more studies become available (See Table 3). Very low quality evidence (1 trial, 60 participants) showed a significant improvement in pain intensity and Neck Pain Disability Scale scores immediately after treatment in the LLLT group compared to placebo in subjects with cervical OA [70]. One RCT with 27 participants, some of whom had underlying cervical OA, found low quality evidence of LLLT for reducing pain immediately and in the short-term [69]. Second, one further study reported dichotomous data for participants with chronic osteoarthritic changes [71]. Very low quality evidence (1 trial, 38 participants) showed that LLLT lead to significant decreases in combined Pain and Karnofsky Function Scale scores [RR 0.30 (95%CI Random: 0.12 to 0.76)] immediately after treatment for subjects with cervical OA [71]. The NNT was 2 for pain and improved pain/disability; there was a treatment advantage of 47 to 71% for pain and 54% for pain/disability, or an absolute benefit of 47 to 50 VAS points and 68 pain/disability points

(max 100). Therefore, a practitioner needs to treat two people to have one person experience about 60% pain relief and 54% pain/disability improvement. Third, one additional study evaluated acute cervical pain with or without degenerative changes [67]. Very low quality evidence (1 trial, 71 participants) showed a significant reduction in pain in the immediate term. The LLLT group had significantly lower rates of pain recurrence at six months [67].

Disorder Subtype 2 - Myofascial Pain Syndrome

For chronic MPS there was diverse and conflicting evidence (Fig. 6). Five trials examined LLLT in patients with chronic MPS [11,12, 61, 64, 69]. The dosage of each of the trials was diverse, and therefore, due to clinical heterogeneity, we decided not to perform a meta-analysis. On the one hand, low quality evidence (1 trial, 27 participants) showed benefit of LLLT for reducing pain immediately and in the short-term [69]. Additionally, another study with 60 participants showed low quality evidence for positive immediate and short-term effects of LLLT for improving function, quality of life and reducing pain [61]. On the other hand, low quality evidence from one RCT with two separate laser arms with two distinct doses of LLLT (24 participants 12 in each arm) investigating the short-term effects of LLLT versus placebo, found no significant difference in pain levels at four weeks between the two groups in subjects with chronic mechanical neck disorder (tendomyosis) [64]. Very low (1 trial, 47 participants) [12] to low quality evidence (1 trial, 36 participants) [11] from two separate studies comparing

Table 3. The Laser Dosage and Clinical Characteristics are Noted for Each Trial

| Author | Laser Characteristics | | | Clinical Characteristics | | | |
|---|---|--|---|---|--|--|-----------|
| | Instrument & Wavelength | Laser Settings | Energy Density | Location | Irradiation Time | Frequency & Duration | Follow-Up |
| Altan 2005 {Altan, 2005 3836 /id} | Roland Serie Elettronica Pagani (Infrared-27) GaAs WL: 904 nm | <i>Drive Technology: Pulsed</i> <i>Pulse Duration: 200 ns (estimate)</i> <i>Pulse Frequency: 1000 Hz</i> <i>Peak Power: 27 W</i> <i>Mean Power: 5.4 mW</i> | TrPt 64.8 J/cm ² | 3 trigger points bilaterally (0.65 J each) and 1 point in the taut bands of the trapezius muscle bilaterally (0.65 J each) Total Dose per session: 5.18 J | TrPt: 120s each point | 5 sessions per week on week days for 2 weeks Total Dosage per program: 51.84 J | 12 weeks |
| Ceccerelli 1989 [69] | NuovaVitiemine R, STC-LE 25 GaAs WL: 904 nm | <i>Drive Technology: Pulsed</i> <i>Pulse Duration: 200 ns</i> <i>Pulse Frequency: 1000 Hz</i> <i>Peak Power: 25 W</i> <i>Mean Power: 5 mW</i> | TrPt: 5 J/cm ² AcuPt: 0.5 J/cm ² | 4 most painful muscular trigger points (1J each) [Total Dose per session:4.00J] and 10 acupuncture points in the cervical zone were (0.1J each) [Total Dose per session: 1.00J] | TrPt: 200s each point AcuPt: 20s each point | 3 sessions per week on alternate days for 4 weeks Total Dosage per program: TrPt 48 J; AcuPt 12 J | 12 weeks |
| Chow 2004 [59] | NR WL: 830 nm | <i>Drive Technology: Continuous</i> <i>Power: 300 mW</i> <i>Power Density: 0.67 W/cm²</i> | 20 J/cm ² | Over tender points in muscles cervical spine muscles Total Dose per session: 9J per point | 30s each point | 2 sessions per week for 7 weeks Total Dosage per program: 136 J per point | 0 weeks |
| Chow 2006 [66] | Diolase Laser WL: 830 nm | <i>Drive Technology: Continuous</i> <i>Power: 300 mW</i> <i>Irradiated Area: 0.45 cm²</i> <i>Power Density: 0.67 W/cm²</i> | 20 J/cm ² | Myofascial trigger points up to a maximum of 50 Total Dose per session: 450 J | 30s each point | 2 sessions per week for 7 weeks Total Dosage per program: 6300 J | 4 weeks |
| Dundar 2007 [60] | Maestro CCM Medicom, Czech GaAsAl WL: 830 nm | <i>Drive Technology: Pulsed</i> <i>Max Power: 450 mW</i> <i>Pulse Frequency: 1000 Hz</i> <i>Power: 58 mW</i> <i>Irradiated Area: 1 cm²</i> <i>Peak Power Density: 5.8 W/cm²</i> | 696 J/cm ² | 3 trigger points bilaterally (6.96 J each) Total Dose per session: 41.76 J | TrPt: 120s each point | 5 sessions per week on week days for 3 weeks Total Dosage per program: 626.40 J | 1 week |
| Gur 2004 [61] | Frankline IR30 Fzyiomed Belgium GaAs Infrared laser WL: 904 nm | <i>Drive Technology: Pulsed</i> <i>Pulse duration: 200 nsec</i> <i>Pulse Frequency: 2800 Hz</i> <i>Max power: 20 W</i> <i>Mean power: 11.2 mW</i> <i>Irradiated area: 1 cm²</i> | 2 J/cm ² | Up to 10 myofascial trigger points as determined by the physiotherapist during each session Total Dose per session: 20.16 J | 180s each point | Daily for 2 weeks except weekends Total Dosage per program: 201.60 J | 10 weeks |
| Hakguder 2003 [62] | Endolaser 476 Enraf-Nonius GaAsAl WL: 780 nm | <i>Drive Technology: Continuous</i> <i>Max power: 10 mW</i> <i>Power output: 5 mW</i> <i>Power density: 25 mW/cm²</i> <i>Irradiated Area: NR</i> | 5 J/cm ² | Active trigger points in neck and upper trapezius region Total Dose per session: 0.98 J | 3 min 16 seconds per trigger point | 10 daily sessions Total Dosage per program: 11.76 J | 3 weeks |
| Ibuldu 2004 [63] | Power Next TOP 250 HeNe Laser WL: 632.8 nm | NR | NR | 3 Myofascial trigger points on each side of the upper trapezius muscle. 2J each point. Total Dose per session: 12 J | NR | 3 sessions per week for 4 weeks Total Dosage per program: 144 J | 6 months |
| Konstantinovic 2010 [72] | Enraf-Nonius WL: 905 nm | <i>Drive Technology:pulsed</i> <i>Max power: 25 mW</i> <i>Peak Power Density: 12 W/cm²</i> <i>Frequency: 5000 Hz</i> | 2 J/cm ² | 2.5 cm and 3.5 cm laterally from involved spinous process and the two next distal spinal segments (6 points) Total Dose per session: 18 J | 120 s per point | 5 times/week for 3 weeks Total Dosage per program: 270 J | 0 weeks |
| Nilsson 1995 [68]* | WL: NR | NR | NR | NR Total Dose per session: ? | NR | 6 sessions over 3 weeks Total Dosage per program: ? | 1 week |

(Table 3) contd.....

| Author | Laser Characteristics | | | Clinical Characteristics | | | |
|--------------------|---|---|---|---|------------------------|---|-----------|
| | Instrument & Wavelength | Laser Settings | Energy Density | Location | Irradiation Time | Frequency & Duration | Follow-Up |
| Özdemir 2001 [70] | Endolaser 476 GaAlAs Laser WL: 830 nm | Drive Technology: Continuous Power: 50 mW Irradiation Area: 0.785cm ² | 0.9 J/cm ² | 12 standardized application points descending in midline of cervical paravertebral muscles Total Dose per session: 9J | 15s each point | 10 consecutive days Total Dosage per program: 90 J | 0 weeks |
| Seidel 2002 [64] | Lasotronic Pocket Therapy MED-130 GaAlAs Laser WL: 830 nm | Group 1 Drive Technology: Continuous Power: 7 mW Irradiation Area: 0.02cm ² Power Density: 350 mW/cm ² Group 2 Drive Technology: Continuous Power: 30 mW Irradiation area: 0.02cm ² Power Density: 1500 mW/cm ² | Group 1 21 J/cm ² Group 2 90 J/cm ² | Group 1 The same 15 acupuncture points as acupuncture group Total Dose per session: 6.30 J Group 2 The same acupuncture points as acupuncture group Total Dose per session: 27.00 J | AcuPt: 1 min per point | 2 session per week for 4 weeks Total Dosage per program: Group 1 - 50.4 J Group 2 - 216 J | 4 weeks |
| Soriano 1996 [67] | GaAs Laser WL : 904 nm | Drive Technology: Pulsed Pulse Duration: 200 ns Pulse Frequency: 10,000 Hz Peak Power:20 W Average Power:40 mW Peak Power Density: 26 W/cm ² | 4 J/cm ² | Used a 2 cm grid system to irradiate painful area of 150µm ² Total Dose per session: 27 J | 0.15s per point | 5 days a week for 2 weeks Total Dosage per program: 210 J | 6 months |
| Taverna 1990[71] | GaA Laser WL: 904 nm | Drive Technology: Pulsed Pulse Duration: 40ns Pulse Frequency: 10,000 Hz Peak Power: 60 W Mean Power: 24 mW | 4.2 J/cm ² | Number of points varied (selected by treater) from 5 to 9 areas of the cervical spine Total Dose per session: 37.80 J | 175s per point | 6 consecutive days per week for 2.5 weeks Total Dosage per program: 567 J | 0 weeks |
| Thorsen 1991 [11] | PL 944 GaAlAs Laser WL: 830 nm | Drive Technology: Continuous Power: 25 mW | NR | 1-5 tender points as determined by treating physiotherapist. 4.5J per point Total Dose per session: 22.50 J | 180s per tender point | 3 sessions per week for 2 weeks Total Dosage per program: 135 J | 1 week |
| Thorsen 1992 [12] | Endolaser 465 EnrafNonius GaAlAs Laser WL: 830 nm | Drive Technology: Continuous Power: 30 mW Irradiated Area: 0.025 cm ² | 3.6 J/cm ² | 0.9J per point for up to 10 tender points Total Dose per session: 9.0 J | 60s per point | 6 sessions over 2 weeks Total Dosage per program: 108 J | 0 weeks |
| Waylonis 1988 [65] | Dynatron 1120 HeNe Laser WL: 632.8 nm | “Standard technique” | NR | Applied to 12 standard acupuncture points in the hand, cervical, shoulder and dorsal areas Total Dose per session: 0.15 J | 15s per point | 2 sets of 5 daily consecutive sessions with 6 week break in between Total Dosage per program: 1.8 J | 4 months |

KEY: NR not reported; WL wavelength; ns nanosecond; Hz Hertz; nm nanometre; mWmilliwatt; J/cm² joules per centimetres squared; s seconds; cm centimetre; J joule; W watt; ns nanoseconds; GaAsgallium arsenide; HeNe helium neon; GaAlAs gallium aluminium arsenide; µm micrometer; NOTE: * The authors believe that based on a previous publication by Gam (1993) "no effect apart from placebo can be expected from such low power laser therapy".

LLLT to placebo laser showed benefits of short-term effects of placebo laser on pain. We fitted a meta-regression model to help explain the heterogeneity in these trials in terms of study-level dosage covariates. Four covariates were entered into the meta-regression model, that is, drive technology, energy density (J/cm²), dosage per session (J) and dosage per treatment program (J). Table 4 notes the analysis results. One covariate, drive technology (super-pulse), increases the chance (p=0.026) for successful outcome in clients with chronic MPS.

Disorder Type 3 – Chronic Neck Pain

Two further trials investigated chronic neck pain [59, 66]. Moderate quality evidence (2 trials, 109 participants) from a meta-analysis of the effects of LLLT compared to placebo in patients with chronic cervical pain and demonstrated significantly improved pain intensity [SMD_{pooled} -3.69 (95% CI 7.28 to -0.11)] and function [SMD_{pooled}-5.5 (95% CI -15.48 to -4.49)] heterogeneity is significantly different p=0.00001, I² 96% in both the immediate and intermediate terms [59, 66]. Reasons to

| Analysis of Variance | | | | | |
|------------------------------|----|------|------|-------|-------|
| SMD vs DT | | | | | |
| Source | DF | SS | MS | F | P |
| Regression | 1 | 4.04 | 4.04 | 10.79 | 0.030 |
| Residual Error | 4 | 1.50 | 0.37 | | |
| Total | 5 | 5.54 | | | |
| SMD vs Energy Density | | | | | |
| Source | DF | SS | MS | F | P |
| Regression | 1 | 0.18 | 0.18 | 0.14 | 0.728 |
| Residual Error | 4 | 5.36 | 1.34 | | |
| Total | 5 | 5.54 | | | |
| SMD vs D/Sess | | | | | |
| Source | DF | SS | MS | F | P |
| Regression | 1 | 1.59 | 1.59 | 1.62 | 0.272 |
| Residual Error | 4 | 3.94 | 0.98 | | |
| Total | 5 | 5.54 | | | |
| SMD vs D/Prog | | | | | |
| Source | DF | SS | MS | F | P |
| Regression | 1 | 0.95 | 0.95 | 0.83 | 0.414 |
| Residual Error | 4 | 4.59 | 1.14 | | |
| Total | 5 | 5.54 | | | |

KEY: SMD standard mean difference; DF - drive force; SS - sum of squares; D/Sess - dose per session; D/Prog - dose per program; MS - mean square.

Fig. (5). Meta-regression for four clinically relevant dosage factors yielded the following regression equation for drive technology (SMD = -2.70 + 1.74 DT).




Fig. (6). Chronic myofascial pain syndrome at 2 to 4w, 8 to 15 sessions of treatment using a 830 nm or 904 nm LLLT wavelength.

explain the heterogeneity of the populations included in these two studies were explored. However, no differences in characteristics of the patients, including age, gender and pain intensity, could be determined, and therefore, the heterogeneity that exists cannot be explained.

Despite the moderate quality of evidence that is obtained from these two trials, limitations do exist and need to be considered when interpreting the results [59, 66]. One major limitation is the presence of a selection bias, as the same research group carried out both trials. The possibility of a failure of blinding, in addition to exposure-suspicion bias, also exists, which lead to better outcomes being reported by those in the treatment group.

Disorder Subtype 4 – Acute Neck Pain with Radiculopathy

Low quality evidence (one trial, 60 participants) suggests LLLT improved pain, function and quality of life immediately post 3 weeks (15 sessions) of treatment when compared to a placebo [72].

LLLT (830 nm or 904 nm) + Exercise versus Placebo Laser + Exercise

Very low quality evidence from two trials (48 participants {Altan, 2005 3836 /id}; 64 participants [60]) examined the short-term effect of LLLT (830 nm or 904 nm) versus placebo laser with exercise in the treatment of chronic MPS. Both studies found no significant difference in pain between study groups immediately post-treatment. {Altan, 2005 3836 /id; Dundar, 2007 2816 /id}

LLLT (780 nm) + Exercise Versus Exercise

Low quality evidence from one trial with 62 participants examined the short-term effect of LLLT combined with exercise versus exercise alone in the treatment of MPS [62]. The laser combined with exercise group showed a significant reduction in pain compared to the exercise alone group immediately after treatment, which was sustained for three weeks [SMD -1.24 (95% CI: -1.78 to -0.69)] [62]. Therefore,

Table 4. GRADE Assessment of Included Studies

| Quality Assessment | | | | | | | Summary of Findings | | | | |
|--|-------------------------|--------------|---------------|---|---------------------------------------|-----------------------|------------------------|-------------------|---|--|-----------------|
| Study | Design Follow-Up Period | Limit Ations | Inconsistency | Indirectness (Generalizability; Group Size) | Imprecision (Sparse Data; Group Size) | Other Consider Ations | No of Patients | | Effect | | Quality (GRADE) |
| | | | | | | | Intervention (Group A) | Control (Group B) | Relative Effect Size (95% CI) --- Pooled Effect Size (95% CI) | Absolute Benefit, Treatment Advantage, NNT | |
| GaAIs 830 nm or GaAs 904 nm Laser Versus Placebo Laser | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Ceccherelli 1989 [69] Chronic myofascial pain syndrome at IT | 0 | 0 | na | 0 | -1 | -1 | 13 | 14 | SMD -1.74 (-2.64, -0.83) | AB Group A 38.23 Group B -6.36 TA 71% NNT 2 | Low |
| Gur 2004 [61] Chronic myofascial pain syndrome at ST | 0 | -1 | na | 0 | 0 | -1 | 30 | 30 | SMD -0.97 (-1.54, -0.41) | AB Group A 3.11 Group B 5.79 TA 35% NNT 3 | Low |
| Chow 2004 [59] Myofascial pain syndrome at IT | 0 | 0 | na | 0 | -1 | 0 | 10 | 9 | SMD pooled -3.69 (-7.28, -0.11) | AB Group A 2.1 Group B 0.7 TA 32% NNT 4 | Moderate |
| Chow 2006 [66] Chronic neck pain at ST | | | | | | | 45 | 45 | | AB Group A 2.7 Group B 0.3 TA 53% NNT 2 | |
| Konstantinovic 2010 [72] Acute neck pain with radiculopathy at ST | 0 | 0 | na | 0 | -1 | -1 | 30 | 30 | SMD -0.60 (-1.14, -0.06) | AB Group A 23.49 Group B 19.00 TA 8.8% NNT 17 | Low |
| Ozdemir 2001[70] Cervical osteoarthritis Duration NR at ST | 0 | -1 | na | 0 | -1 | -1 | 30 | 30 | SMD -3.86 (-4.73, -2.98) | AB Group A 5.3 Group B 0.5 TA 62% NNT 2 | Very Low |
| Thorsen 1991 [11] Chronic myofascial pain syndrome at ST | 0 | 0 | na | 0 | -1 | -1 | 19 | 17 | SMD 0.72 (0.04, 1.40) | AB Group A -1.4 Group B 1.2 | Low |
| Thorsen 1992 [12] Chronic myofascial pain syndrome at ST | -1 | -1 | na | 0 | -1 | -1 | 25 | 22 | SMD 0.89 (0.29, 1.49) | AB Group A 0.15 Group B 0.30 | Very Low |

(Table 4) contd.....

| Quality Assessment | | | | | | | Summary of Findings | | | | |
|--|-------------------------|--------------|---------------|---|---------------------------------------|-----------------------|------------------------|-------------------|---|---|-----------------|
| Study | Design Follow-Up Period | Limit Ations | Inconsistency | Indirectness (Generalizability; Group Size) | Imprecision (Sparse Data; Group Size) | Other Consider Ations | No of Patients | | Effect | | Quality (GRADE) |
| | | | | | | | Intervention (Group A) | Control (Group B) | Relative Effect Size (95% CI) --- Pooled Effect Size (95% CI) | Absolute Benefit, Treatment Advantage, NNT | |
| GaAIs 830 nm or GaAs 904 nm Laser Versus Placebo Laser | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Seidel 2002 [64] Chronic myofascial pain syndrome (tendomyosis) 7 mW at ST | 0 | 0 | na | 0 | -1 | -1 | 12 | 12 | SMD -0.29 (-1.10, 0.51) | AB Group A 20.0 Group B 14.5 | Low |
| Seidel 2002 [64] Chronic myofascial pain syndrome (tendomyosis) 30 mW at ST | 0 | 0 | na | 0 | -1 | -1 | 12 | 12 | SMD 0.83 (-0.01, 1.67) | AB Group A 9.9 Group B 14.5 | Low |
| Soriano 1996 [67] Acute cervical pain at IT | 0 | -1 | na | -1 * # | -1 | -1 | 37 | 34 | RR 0.39 (0.24, 0.64) | TA 50%; NNT 3 | Very Low |
| Function/Disability | | | | | | | | | | | |
| Chow 2004 [59] Myofascial pain syndrome at IT | 0 | 0 | na | 0 | -1 | 0 | 10 | 9 | SMD pooled -5.5 (-15.48, -4.49) | AB Group A -0.12 Group B -0.007 TA 30.1% NNT 8 | Moderate |
| Chow 2006 [66] Chronic neck pain at ST | | | | | | | 45 | 45 | | | |
| Dundar 2007 [60] Chronic myofascial pain syndrome at ST | 0 | -1 | na | 0 | -1 | -1 | 32 | 32 | SMD -0.41 (-0.90, 0.09) | AB Group A 10.6 Group B 7.1 | Very Low |
| Gur 2004 [61] Chronic myofascial pain syndrome at ST | 0 | -1 | na | 0 | 0 | -1 | 30 | 30 | SMD -0.82 (-1.38, -0.26) | AB Group A 38.45 Group B 61.87 TA 29% NNT 4 | Low |
| Konstantinovic 2010 [72] Acute neck pain with radiculopathy at ST | 0 | 0 | na | 0 | -1 | -1 | 30 | 30 | SMD -0.68 (-1.22, -0.14) | AB Group A 29.84 Group B 25.13 TA 6.5% NNT 7143 | Low |

(Table 4) contd.....

| Quality Assessment | | | | | | | Summary of Findings | | | | |
|--|-------------------------|--------------|---------------|---|---------------------------------------|-----------------------|------------------------|-------------------|---|--|-----------------|
| | | | | | | | No of Patients | | Effect | | Quality (GRADE) |
| Study | Design Follow-Up Period | Limit Ations | Inconsistency | Indirectness (Generalizability; Group Size) | Imprecision (Sparse Data; Group Size) | Other Consider Ations | Intervention (Group A) | Control (Group B) | Relative Effect Size (95% CI) --- Pooled Effect Size (95% CI) | Absolute Benefit, Treatment Advantage, NNT | |
| GaAIs 830 nm or GaAs 904 nm Laser Versus Placebo Laser | | | | | | | | | | | |
| Function/Disability | | | | | | | | | | | |
| Ozedemir 2001 [70] Cervical osteoarthritis Duration NR at ST | 0 | -1 | na | 0 | -1 | -1 | 30 | 30 | SMD -4.51 (-5.48, -3.53) | AB Group A 68.1, Group B 6.8 TA 62% NNT 2 | Very Low |
| Global Perceived Effect | | | | | | | | | | | |
| Chow 2004 [59] Myofascial pain syndrome at IT | 0 | 0 | na | 0 | -1 | 0 | 10 | 10 | SMD pooled -8.93 (-24.07, 6.20) | AB Group A 66.7% Group B 16.6% | Moderate |
| Chow 2006 [66] Chronic neck pain at ST | | | | | | | 45 | 45 | | AB Group A 43.8 Group B 2.1 | |
| Quality of Life | | | | | | | | | | | |
| Chow 2004 [59] Myofascial pain syndrome at IT | 0 | 0 | na | 0 | -1 | 0 | 10 | 10 | SMD pooled -3.43 (-9.42, 2.56) | AB Group A 4.0 Group B 1.22 | Moderate |
| Chow 2006 [66] Chronic neck pain at ST | | | | | | | 45 | 45 | | AB Group A 3.2, Group B -1.3 | |
| Gur 2004 [61] Chronic myofascial pain syndrome at ST | 0 | -1 | na | 0 | 0 | -1 | 30 | 30 | SMD -0.58 (-1.13, -0.04) | AB Group A 41.48 Group B 69.61 TA 28.6% NNT 3 | Low |
| Konstantinovic 2010 [72] Acute neck pain with radiculopathy at ST | 0 | 0 | na | 0 | -1 | -1 | 30 | 30 | SMD -0.96 (-1.68, -0.24) | AB Group A 5.00 Group B 4.10 TA 8.0% NNT 252 | Low |
| Pain and Function Combined | | | | | | | | | | | |
| Taverna 1990 [71] Cervical osteoarthritis Duration NR at ST | 0 | -1 | na | 0 | -1 | -1 | 20 | 18 | RR 0.30 (0.12, 0.76) | TA 47% NNT 3 | Very Low |

(Table 4) contd.....

| Quality Assessment | | | | | | | Summary of Findings | | | | |
|---|-------------------------|--------------|---------------|---|---------------------------------------|-----------------------|------------------------|-------------------|---|--|-----------------|
| | | | | | | | No of Patients | | Effect | | Quality (GRADE) |
| Study | Design Follow-Up Period | Limit Ations | Inconsistency | Indirectness (Generalizability; Group Size) | Imprecision (Sparse Data; Group Size) | Other Consider Ations | Intervention (Group A) | Control (Group B) | Relative Effect Size (95% CI) --- Pooled Effect Size (95% CI) | Absolute Benefit, Treatment Advantage, NNT | |
| GaAlAs 830 nm or GaAs 904 nm Laser + Exercise vs Placebo Laser + Exercise | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Altan 2005 {Altan, 2005 3836 /id} Chronic myofascial pain syndrome at IT | 0 | -1 | na | 0 | -1 | -1 | 23 | 25 | SMD -1.14 (-1.75, -0.52) | AB Group A 3.68 Group B 2.44 | Very Low |
| Dundar 2007 [60] Chronic myofascial pain syndrome at ST | 0 | -1 | na | 0 | -1 | -1 | 32 | 32 | SMD 0.00(-0.49, 0.49) | AB Group A 0.9 Group B 1.0 | Very Low |
| GaAsAl 780 nm Laser + Exercise vs Exercise | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Hakguder 2003 [62] Myofascial pain syndrome Duration NR at ST | 0 | 0 | na | 0 | -1 | -1 | 31 | 31 | SMD -1.24 (-1.78, -0.69) | AB Group A 4.48 Group B 1.84 NNT 4 TA 33% | Low |
| GaAlAs 830 nm or GaAs 904 nm Laser and Deep Friction Massage vs Manipulation | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Nilsson 1995 [68] Chronic cervicogenic headache at ST | 0 | -1 | na | -1 * † | -1 | -1 | 18 | 20 | SMD 0.45 (-0.10, 0.94) | AB Group A 31 Group B 33 | Very Low |
| GaAlAs 830 nm or GaAs 904 nm Laser vs Acupuncture | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Seidel 2002 [64] Chronic myofascial pain syndrome (tendomyosis) 7 mW at ST | 0 | 0 | na | 0 | -1 | -1 | 12 | 12 | SMD -0.29 (-1.10, 0.51) | AB Group A 20.0 Group B 29.9 | Low |
| Seidel 2002 [64] Chronic myofascial pain syndrome (tendomyosis) 30 mW at ST | 0 | 0 | na | 0 | -1 | -1 | 12 | 12 | SMD 0.83 (-0.01, 1.67) | AB Group A 9.9 Group B 29.9 | Low |

(Table 4) contd.....

| Quality Assessment | | | | | | | Summary of Findings | | | | |
|--|-------------------------|--------------|---------------|---|---------------------------------------|-----------------------|------------------------|-------------------|---|--|-----------------|
| Study | Design Follow-Up Period | Limit Ations | Inconsistency | Indirectness (Generalizability; Group Size) | Imprecision (Sparse Data; Group Size) | Other Consider Ations | No of Patients | | Effect | | Quality (GRADE) |
| | | | | | | | Intervention (Group A) | Control (Group B) | Relative Effect Size (95% CI) --- Pooled Effect Size (95% CI) | Absolute Benefit, Treatment Advantage, NNT | |
| He-Ne 632.8 nm Laser vs Placebo Laser | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Waylonis 1988 [65] Chronic myofascial pain syndrome at ST | -1 | -1 | na | -1 * ¶ | -1 | -1 | NR | NR | Baseline Data NR | Baseline Data NR | Very Low |
| He-Ne laser 632.8 nm + Exercise vs Placebo Laser + Exercise | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Ilbuldu 2004 [63] Chronic myofascial pain syndrome at IT | 0 | -1 | na | -1 * † § | -1 | -1 | 20 | 20 | SMD -0.89 (-1.55, -0.24) | AB Group A 3.4 Group B 2.0 | Very Low |
| Function | | | | | | | | | | | |
| Ilbuldu 2004 [63] Chronic myofascial pain syndrome at IT | 0 | -1 | na | -1 * † § | -1 | -1 | 20 | 20 | SMD -0.58 (-1.22, 0.05) | AB Group A 41.03 Group B 28.26 | Very Low |
| He-Ne Laser 632.8 nm + Exercise vs Dry Needling + Exercise | | | | | | | | | | | |
| Pain | | | | | | | | | | | |
| Ilbuldu 2004 [63] Chronic myofascial pain syndrome at IT | 0 | -1 | na | -1 * † § | -1 | -1 | 20 | 20 | SMD -0.84 (-1.49, -0.19) | AB Group A 3.4 Group B 1.4 | Very Low |
| Function | | | | | | | | | | | |
| Ilbuldu 2004 [63] Chronic myofascial pain syndrome at IT | 0 | -1 | na | -1 * † § | -1 | -1 | 20 | 20 | SMD -0.71 (-1.35, -0.07) | AB Group A 41.03 Group B 36.15 | Very Low |

KEY: RCT randomized controlled trial; ST short-term closest to 4 weeks; IT intermediate-term; LT long-term 6 months+; LLLT low level laser therapy; na not applicable; NNT number needed to treat; TA treatment advantage; SMD standard mean deviation; RR relative risk; NR not reported; Acute < 30 days; Chronic > 90 days; * single trial; † Treatment used not reproducible; § small sample size; || recruitment or description of recruitment center process is not described; ¶ Insufficient baseline data of subjects; # Insufficient information on outcome measure not given/ Validated outcome measure not used.

a practitioner needs to treat four people to have one person experience 33% more pain relief than exercise alone or an absolute benefit of 50 point VAS pain change from baseline.

LLLT + Deep Friction Massage Versus Manipulation

Very low quality evidence (1 trial, 38 participants) assessed the effects of massage and LLLT compared to manipulation in participants with cervicogenic headache showed no significant pain relief in the short-term [68].

LLLT (830 nm) Versus Acupuncture

There is low quality evidence (1 trial, 12 participants) of no benefit in pain intensity at four weeks follow-up when LLLT was compared to acupuncture for tenomyositis in the short-term [64].

Clinical Applicability

There was a wide variety in the clinical applicability of the included trials (Fig. 2) with Gur *et al.* [61] having the most clinically relevant intervention.

Other Considerations

Adverse Events and Cost of Care

Benign and self-limiting side effects were reported in six studies [12, 59, 61, 65, 66, 72].

DISCUSSION

The results of our review vary by disorder subtype, laser parameters and laser characteristics. For chronic neck pain, there was moderate quality evidence supporting the use of LLLT over placebo to improve pain, disability, QoL and GPE in the short and intermediate-term. For acute radiculopathy, low quality evidence suggested that LLLT improves short-term pain, function and QoL over a placebo. For chronic MPS, there was unclear evidence regarding the use of LLLT (HeNe 632.8 nm, GaAlAs 830 nm, GaAs 904 nm) in decreasing pain and improving function in patients. Insight from the meta-regression analysis of these trials suggests that drive technology (super-pulse) may increase the chance of successful treatment for this group of patients. When combined with exercise, laser has varied results with differing laser parameters. First, no evidence of benefit has been shown for the use of LLLT (830 nm or 904 nm) plus exercise for decreasing pain in subjects with MPS over exercise alone. Alternatively, when combined with exercise, LLLT 780 nm has been shown to decrease pain in patients with chronic MPS. When combined with deep friction massage, LLLT shows no benefit in decreasing cervicogenic headache intensity. For cervical osteoarthritis or acute neck pain, low to very low quality evidence support the use of LLLT to improve ST and IT pain and function albeit the two positive trials were clinically and statistically heterogenous and trial results could not be pooled.

Our systematic review investigates the effectiveness of LLLT in the treatment of neck pain and has several strengths. The GRADE method of analysis used in this systematic review provides information not only on the internal validity (risk of bias) of all included studies, but also external validity (design, limitations, inconsistency, indirectness, imprecision, other considerations). This, along with the clinical applicability assessment included in our review, helps to increase the generalizability and translation of our results into clinical practice. Additionally, we included studies published in languages other than English, which decreases the risk of potential language bias that could skew results. This review is not void of limitations. The doses, types of lasers, frequencies of treatment, and poor descriptions made some meta-analysis inappropriate. Many of the studies did not describe the conditions of participants in detail, thus limiting the applicability of results. The vast majority of the studies examined the effects of laser on pain and a few assessed whether there were significant changes in function, global perceived effect, or quality of life. When positive, we did translate the evidence to clinically meaningful terms including the magnitude of the effect and NNT. All of the studies had small sample sizes and few male subjects were included. Generalizability is therefore a pivotal limiting factor in our findings of predominately low and very low quality.

Our results are consistent with other current reviews investigating the effectiveness of LLLT. A systematic review by Chow and colleagues showed the benefit of LLLT for

acute and chronic neck pain both in the short and intermediate terms [41]. The effects of LLLT have also been studied in patients with acute and chronic nonspecific low-back pain in a systematic review by Yousefi-Nooraie and colleagues [73]. Their study showed that LLLT leads to significant improvements in pain relief in the short and intermediate terms, with some evidence that LLLT reduces short-term disability [73].

The optimal treatment parameters for LLLT have yet to be clearly identified and have been the 'Achilles' heel' to establishing sound meta-analyses [20, 74]; dosage trials for each subtype disorder are warranted. Based on the studies included in our review, combined with the results of our meta-regression, we note the following LLLT dosage characteristics for the treatment of patients with cervical pain caused by chronic MPS, chronic neck pain or osteoarthritis were used: Drive technology: super-pulse LLLT; Location: cervical trigger point(s); Time: 30 to 196 seconds; Frequency: 2 to 7 days per week; and Duration: 10 days to 7 weeks. In future research, trials need larger sample sizes, outcomes that measure function, quality of life and global perceived effect, longer follow-up time periods, and consistent comparisons. Trials are also required to define dosage factors that lead to the most beneficial outcomes, as only one study compared dose parameters [64]. Additionally, more human trials need to be conducted to increase understanding of the underlying mechanism of action of laser on neck pain.

CONCLUSION

We found diverse evidence for the use of LLLT in the treatment of various subtypes of neck pain. We found moderate quality evidence in favour of LLLT for chronic neck pain indicating further research is likely to have an important impact on our confidence in the estimate of effect and may change this estimate. Our results suggest that there is mostly very low to low quality evidence available, indicating a lot of uncertainty. Our meta-regression suggests drive technology (super-pulse) may increase the chance of success in treatment of patients with chronic MPS. Future studies with larger sample sizes are needed to explore the functional outcomes of LLLT in the treatment of neck pain, to compare different types of laser, and to further our understanding of the dosage parameters of LLLT in the treatment of neck pain.

CONFLICT OF INTEREST

Roger White, BSc., is president and CEO of Theralase Inc. His products were not assessed in any of the retrieved trials; there was no financial support received from his company.

ACKNOWLEDGEMENTS

Centric HealthLifemark is a multidisciplinary health care private service that is the Cervical Overview Group's industry partner and provided funding administered independently through McMaster University. It has no financial interest in low level laser therapy.

We also thank Centric Health-Lifemark for being our industry partner and for their generous financial support. We thank Dr Pam Houghton (PhD) for being a consultant to this project.

APPENDIX A

COG Detailed MEDLINE Search Strategy for Physical Medicine Methods

| | | |
|---|--|---|
| 1. Neck Pain/ | 52. cervico*.mp. | 98. (thoracic adj3 vertebrae).mp. |
| 2. exp Brachial Plexus Neuropathies/ | 53. 51 or 52 | 99. cervical.mp. |
| 3. exp neck injuries/ or exp whiplash injuries/ | 54. exp genital diseases, female/ | 100. cervico*.mp. |
| 4. cervical pain.mp. | 55. genital disease*.mp. | 152. Fibromyalgia/rh |
| 5. neckache.mp. | 56. exp *Uterus/ | 153. spondylitis/rh or discitis/rh |
| 6. whiplash.mp. | 57. 54 or 55 or 56 | 154. spondylosis/rh or spondylolysis/rh or spondylolisthesis/rh |
| 7. cervicodynia.mp. | 58. 53 not 57 | 155. or/144-154 |
| 8. cervicalgia.mp. | 59. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 58 | 156. 59 and 155 |
| 9. brachialgia.mp. | 60. exp pain/ | 157. exp Combined Modality Therapy/ |
| 10. brachial neuritis.mp. | 61. exp injuries/ | 158. Exercise/ |
| 11. brachial neuralgia.mp. | 62. pain.mp. | 159. Physical Exertion/ |
| 12. neck pain.mp. | 63. ache.mp. | 160. exp Exercise Therapy/ |
| 13. neckinjur*.mp. | 64. sore.mp. | 161. exp Electric Stimulation Therapy/ |
| 14. brachial plexus neuropath*.mp. | 65. stiff.mp. | 162. Transcutaneous Electric Nerve Stimulation/ |
| 15. brachial plexus neuritis.mp. | 66. discomfort.mp. | 163. pulsedelectro magnetic field.mp. |
| 16. thoracic outlet syndrome/ or cervical rib syndrome/ | 67. injur*.mp. | 164. pulsed electromagnetic field.tw. |
| 17. Torticollis/ | 68. neuropath*.mp. | 165. Electromagnetic Fields/ |
| 18. exp brachial plexus neuropathies/ or exp brachial plexus neuritis/ | 69. or/60-68 | 166. Magnetic Field Therapy/ |
| 19. cervico brachial neuralgia.ti,ab. | 70. 59 and 69 | 167. Electric Stimulation/ |
| 20. cervicobrachialneuralgia.ti,ab. | 71. Radiculopathy/ | 168. exp Orthotic Devices/ |
| 21. (monoradicul* or monoradicl*).tw. | 72. exptemporomandibular joint disorders/ or exptemporomandibular joint dysfunction syndrome/ | 169. kinesiotaping.tw. |
| 22. or/1-21 | 73. myofascial pain syndromes/ | 170. taping.tw. |
| 23. exp headache/ and cervic*.tw. | 74. exp "Sprains and Strains"/ | 171. oral splints.tw. |
| 24. exp genital diseases, female/ | 75. exp Spinal Osteophytosis/ | 172. Occlusal Splints/ |
| 25. genital disease*.mp. | 76. exp Neuritis/ | 173. pillow?.tw. |
| 26. or/24-25 | 77. Polyradiculopathy/ | 174. collar?.tw. |
| 27. 23 not 26 | 78. exp Arthritis/ | 175. Traction/ |
| 28. 22 or 27 | 79. Fibromyalgia/ | 176. traction.tw. |
| 29. neck/ | 80. spondylitis/ or discitis/ | 177. exp Laser Therapy/ |
| 30. neck muscles/ | 81. spondylosis/ or spondylolysis/ or spondylolisthesis/ | 178. laser therapy.tw. |
| 31. exp cervical plexus/ | 82. radiculopathy.mp. | 179. exp Rehabilitation/ |
| 32. exp cervical vertebrae/ | 83. radiculitis.mp. | 180. Ultrasonic Therapy/ |
| 33. atlanto-axial joint/ | 84. temporomandibular.mp. | 181. exp Phototherapy/ |
| 34. atlanto-occipital joint/ | 85. myofascial pain syndrome*.mp. | 182. Lasers/ |
| 35. Cervical Atlas/ | 86. thoracic outlet syndrome*.mp. | 183. exp Physical Therapy Modalities/ |
| 36. spinal nerve roots/ | 87. spinal osteophytosis.mp. | 184. repetitive magnetic stimulation.tw. |
| 37. exp brachial plexus/ | 88. neuritis.mp. | 185. expCryotherapy/ |
| 38. (odontoid* or cervical or occip* or atlant*).tw. | 89. spondylosis.mp. | 186. Hydrotherapy/ |
| 39. axis/ or odontoid process/ | 90. spondylitis.mp. | 187. exp Hyperthermia, Induced/ |
| 40. Thoracic Vertebrae/ | 91. spondylolisthesis.mp. | 188. vapocoolant spray.mp. |
| 41. cervical vertebrae.mp. | 92. or/71-91 | 189. Cryoanesthesia/ |
| 42. cervical plexus.mp. | 93. 59 and 92 | 190. Ice/ |
| 43. cervical spine.mp. | 94. exp neck/ | 191. postur* correction.mp. |
| | 95. exp cervical vertebrae/ | 192. Feldenkrais.mp. |
| | 96. Thoracic Vertebrae/ | 193. (alexanderadj (technique or method)).tw. |
| | 97. neck.mp. | 194. Relaxation Therapy/ |
| | | 195. Biofeedback, Psychology/ |
| | | 196. faradic stimulation.mp. |
| | | 197. or/157-196 |
| | | 198. 136 and 197 |
| 44. (neck adj3 muscles).mp. | | |
| 45. (brachial adj3 plexus).mp. | | |
| 46. (thoracic adj3 vertebrae).mp. | | |
| 47. neck.mp. | | |
| 48. (thoracic adj3 spine).mp. | | |
| 49. (thoracic adj3 outlet).mp. | | |
| 50. trapezius.mp. | | |
| 51. cervical.mp. | | |
| 101. 99 or 100 | | |
| 102. exp genital diseases, female/ | | |
| 103. genital disease*.mp. | | |
| 104. exp *Uterus/ | | |
| 105. or/102-104 | | |
| 106. 101 not 105 | | |
| 107. (thoracic adj3 spine).mp. | | |
| 108. cervical spine.mp. | | |
| 109. 94 or 95 or 96 or 97 or 98 or 106 or 107 or 108 | | |
| 110. Intervertebral Disk/ | | |
| 111. (disc or discs).mp. | | |
| 112. (disk or disks).mp. | | |
| 113. 110 or 111 or 112 | | |
| 114. 109 and 113 | | |
| 115. herniat*.mp. | | |
| 116. slipped.mp. | | |
| 117. prolapse*.mp. | | |
| 118. displace*.mp. | | |
| 119. degenerat*.mp. | | |
| 120. (bulge or bulged or bulging).mp. | | |
| 121. 115 or 116 or 117 or 118 or 119 or 120 | | |
| 122. 114 and 121 | | |
| 123. intervertebral disk degeneration/ or intervertebral disk displacement/ | | |
| 124. intervertebral disk displacement.mp. | | |
| 125. intervertebral disc displacement.mp. | | |
| 126. intervertebral disk degeneration.mp. | | |
| 127. intervertebral disc degeneration.mp. | | |
| 128. 123 or 124 or 125 or 126 or 127 | | |
| 129. 109 and 128 | | |
| 130. 28 or 70 or 93 or 122 or 129 | | |
| 131. animals/ not (animals/ and humans/) | | |
| 132. 130 not 131 | | |
| 133. exp *neoplasms/ | | |
| 134. exp *wounds, penetrating/ | | |
| 135. 133 or 134 | | |
| 136. 132 not 135 | | |
| 137. Neck Pain/rh [Rehabilitation] | | |

| | |
|--|--|
| 138. exp Brachial Plexus Neuropathies/rh | 199. 143 or 156 or 198 |
| 139. exp neck injuries/rh or exp whiplash injuries/rh | 200. animals/ not (animals/ and humans/) |
| 140. thoracic outlet syndrome/rh or cervical rib syndrome/rh | 201. 199 not 200 |
| 141. Torticollis/rh | 202. exp randomized controlled trials as topic/ |
| 142. exp brachial plexus neuropathies/rh or exp brachial plexus neuritis/rh | 203. randomized controlled trial.pt. |
| 143. 137 or 138 or 139 or 140 or 141 or 142 | 204. controlled clinical trial.pt. |
| 144. Radiculopathy/rh | 205. (random* or sham or placebo*).tw. |
| 145. exptemporomandibular joint disorders/rh or exptemporomandibular joint dysfunction syndrome/rh | 206. placebos/ |
| 146. myofascial pain syndromes/rh | 232. review literature as topic/ |
| 147. exp "Sprains and Strains"/rh | 233. (collaborative research or collaborative review* or collaborative overview*).tw. |
| 148. exp Spinal Osteophytosis/rh | 234. (integrative research or integrative review* or intergrative overview*).tw. |
| 149. exp Neuritis/rh | 235. (quantitative adj3 (research or review* or overview*).tw. |
| 150. Polyradiculopathy/rh | 236. (research integration or research overview*).tw. |
| 151. exp Arthritis/rh | 237. (systematic* adj3 (review* or overview*).tw. |
| 207. random allocation/ | 238. (methodologic* adj3 (review* or overview*).tw. |
| 208. single blind method/ | 239. exp technology assessment biomedical/ |
| 209. double blind method/ | 240. (hta or thas or technology assessment*).tw. |
| 210. ((singl* or doubl* or trebl* or tripl*) adj25 (blind* or dumm* or mask*).ti,ab. | 241. ((hand adj2 search*) or (manual* adj search*).tw. |
| 211. (rct or rcts).tw. | 242. ((electronic adj database*) or (bibliographic* adj database*).tw. |
| 212. (control* adj2 (study or studies or trial*).tw. | 243. ((data adj2 abstract*) or (data adj2 extract*).tw. |
| 213. or/202-212 | 244. (analys* adj3 (pool or pooled or pooling)).tw. |
| 214. 201 and 213 | 245. mantel haenszel.tw. |
| 215. limit 214 to yr="2006 - Current" | 246. (cohrane or pubmed or pub med or medline or embase or psycinfo or psyclit or psychinfo or psychlit or cinahl or science citation indes).ab. |
| 216. limit 214 to yr="1902 - 2005" | 247. or/229-246 |
| 217. guidelines as topic/ | 248. 201 and 247 |
| 218. practice guidelines as topic/ | 249. limit 248 to yr="2006 - Current" |
| 219. guideline.pt. | |
| 220. practice guideline.pt. | |
| 221. (guideline? or guidance or recommendations).ti. | |
| 222. consensus.ti. | |
| 223. or/217-222 | |
| 224. 201 and 223 | |
| 225. 136 and 223 | |
| 226. 224 or 225 | |
| 227. limit 226 to yr="2006 - Current" | |
| 228. limit 226 to yr="1902 - 2005" | |
| 229. meta-analysis/ | |
| 230. exp meta-analysis as topic/ | |
| 231. (meta analy* or metaanaly* or met analy* or metanaly*).tw. | |

* Note: Additional search strategies may be requested by author.

REFERENCES

- Guzman J, Hurwitz E, Carroll L, *et al.* A new conceptual model of neck pain. Linking onset, course, and care: The Bone and Joint Decade 2000-2010 Task Force on Neck Pain and its Associated Disorders. *Spine* 2008; 33: S14-S23.
- Tsakitzidis G, Remmen R, Peremans L, *et al.* Non-specific neck pain: diagnosis and treatment. *Good Clinical Practice (GCP)*. Brussels: KCE Reports 119C 2009.
- Fejer R, Kyvik K, Hartvigsen J. The prevalence of neck pain in the world population: a systematic critical review of the literature. *Eur Spine J* 2006; 15: 834-48.
- Hogg-Johnson S, Van der Velde GM, Carroll LJ, *et al.* The burden and determinants of neck pain in the general population: results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. *Spine (Phila Pa 1976)* 2008; 33(4 Suppl): S39-S51.
- Leroux I, Dionne CE, Bourbonnais R, Brisson C. Prevalence of musculoskeletal pain and associated factors in the Quebec working population. *International Arch Occup & Environ Health* 2005; 78: 379-86.
- Cote P, Kristman V, Vidmar M, *et al.* The prevalence and incidence of work absenteeism involving neck pain: a cohort of Ontario lost-time claimants. *J Manipulative Physiol Ther* 2009; 32(2 Suppl): S219-S226.
- Hurwitz EL, Carragee EJ, Van der Velde GM, *et al.* Treatment of neck pain: Noninvasive interventions: Results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. *J Manipulative Physiol Ther* 2009 Feb; 32(2 Suppl): S141-S175.
- Prentice W, Quillen W, Underwood F. *Therapeutic Modalities in Rehabilitation*. New York: McGraw-Hill; 2005.
- Kenneth K, Draper D. *Therapeutic modalities: the art and the science*. Philadelphia: Lippincott Williams & Wilkins 2008.
- Davis C. *Complementary Therapies in Rehabilitation: Evidence for Efficacy in Therapy, Prevention, and Wellness*. 3rd ed. New Jersey: SLACK Incorporated 2009.
- Thorsen H. Low energy laser treatment therapy effects on localized fibromyalgia in the neck and shoulder regions. [Danish]. *Ugeskrift for Laeger* 1991; 153(25): 1801-4.
- Thorsen H. Low level laser therapy for myofascial pain in the neck and shoulder girdle. A double-blind, cross-over study. *Scand J Rehabil Med* 1992; 21(3): 139-41.
- Kolarova H, Ditrichova D, Wagner J. Penetration of the laser light into the skin *in vitro*. *Lasers Surg & Med* 1999; 24(3): 231-5.
- Young S, Dyson M, Iton P. Effect of light on calcium uptake by macrophages. *Laser Therapy* 1990; 2: 53-7.
- Karu T, Ryabykh TP, Fedoseyeva GA, Puchkova NI. Helium-Neon laser induced respiratory burst of phagocytic cells. *Lasers Surg & Med* 1989; 9: 585-8.
- Lubart R, Freidmann H, Sinyakov M, *et al.* The effect of HeNe Laser (633nm) radiation on intracellular Ca²⁺ concentration in fibroblasts. *Laser Ther* 1997; 9: 115-9.
- Laakso L, Richardson C, Cramond T. Factors affecting low level laser therapy. *Aust J Physiother* 1993; 39: 95-9.
- Basford JR. Low intensity laser therapy: still not an established clinical tool. *Lasers Surg Med* 1995; 16:331-42. *Lasers Surg & Med* 1995; 16: 331-42.
- Chow R, Armati P, Laakso EL, Bjordal JM, Baxter GD. Inhibitory effects of laser irradiation on peripheral mammalian nerves and relevance to analgesic effects: a systematic review. *Photomed Laser Surg* 2011; 29(6): 365-81.
- Bjordal JM, Lopes-Martins R, Johnson MI, Chow R. Inaccuracies in laser therapy meta-analysis for neck pain? *J Physiother* 2010; 56(4): 282.
- King CE, Clelland J, Knowles CJ, Jackson JR. Effect of helium neon laser auriculotherapy on experimental pain threshold. *Phys Ther* 1990; 70: 24-9.
- Maeda T. Morphological demonstration of low reactive laser therapeutic pain attenuation effect of the Gallium Aluminium Arsenide diode laser. *Pain* 1988; 72: 25-30.
- Trelles MA, Mayayo E, Miro L, Rigau J, Baudin G, Calerhead RG. The action of low reactive level laser therapy (LLLT) on mast cells: a possible pain relief mechanism examined. *J Orthop Sports Phys Ther* 2003; 4: 27-30.

- [24] Kramer JF, Sandrin M. Effect of low-power laser and white light on sensory conduction rate of the superficial radial nerve. *Physiother Can* 1993; 45: 165-70.
- [25] Greathouse DG, Currier DP, Gilmore RL. Effects of clinical infrared laser on superficial radial nerve conduction. *Phys Ther* 1985; 65: 1184-7.
- [26] Rochkind S, Rousso M, Nissan M, Villarreal M, Barr-Nea L, Rees DG. Systemic effects of low-power laser irradiation on the peripheral and central nervous system, cutaneous wounds, and burns. *Lasers Surg & Med* 1989; 9: 174-82.
- [27] Belanger A. Laser. Evidence-based guide to therapeutic physical agents. Philadelphia: Lippincott Williams & Wilkins 2003; pp. 191-221.
- [28] Snyder-Mackler L, Bork C. Effect of helium neon laser irradiation on peripheral nerve sensory latency. *Phys Ther* 1988; 68: 223-5.
- [29] Enwemeka CS, Parker JC, Dowdy DS, *et al.* The efficacy of low-power lasers in tissue repair and pain control: a meta-analysis study. *Photomed Laser Surg* 2004; 22(4): 323-9.
- [30] Woodruff LD, Bounkeo JM, Brannon WM, *et al.* The efficacy of laser therapy in wound repair: A meta-analysis of the literature. *Photomed Laser Surg* 2004; 22(3): 241-7.
- [31] Lee G, Wong E, Zucherman J, Mason DT. Evaluating current understanding of low-level laser light in the management of pain. *US Musculoske Rev* 2011; 6(1): 56-60.
- [32] McKibbin LS DR. Treatment of post herpetic neuralgia using 904nm (infrared) low incident energy laser: A clinical study. *Laser Ther* 2012; 3: 35-9.
- [33] Walker HB, Akhanjee LK, Cooney MM, Goldstein J, Tamayoshi S, Segal-Gidan F. Laser therapy for pain of trigeminal neuralgia. *Clin J Pain* 2012; 3: 183-7.
- [34] Ysla R, Mauley R. Effects of low power infrared laser stimulation on carpal tunnel syndrome: A double blind study. *Arch Phys Med Rehabil* 1985; 66: 577.
- [35] Olavi A, Pekka R, Kolari Pertti J. Effect of the infrared laser therapy at treated and non-treated trigger points. *Acupunc & Electro Res* 1988; 14: 9-14.
- [36] Logdberg-Andersson M, Mutzell S, Hazel A. Low level laser therapy (LLLT) of tendonitis and myofascial pains - A randomized, double blind, controlled study. *Laser Therapy* 1997; 7: 79-85.
- [37] Lewith GT, Machin D. A randomized trial to evaluate the effect of infrared stimulation of local trigger points, versus placebo, on the pain caused by cervical osteoarthritis. *Acupunc & Electro Res* 1981; 6: 277-84.
- [38] Brosseau L, Welch V, Wells G, *et al.* Low level laser therapy (Class I, II, and III) in the treatment of RA (Cochrane Review). *Cochrane Database of Systematic Reviews* 3. 2000. Oxford, Update Software.
- [39] Gross AR, Goldsmith C, Hoving JL, *et al.* Conservative management of mechanical neck disorders: a systematic review. *J Rheumatol* 2007; 34(5): 1083-102.
- [40] Leaver AM, Refshauge KM, Maher CG, McAuley JH. Conservative interventions provide short-term relief for non-specific neck pain: a systematic review. *J Physiother* 2010; 56(2): 73-85.
- [41] Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. [Erratum appears in *Lancet*. 2010; 375(9718): 894]. *Lancet* 2009; 374(9705): 1897-908.
- [42] Langevin P, Peloso PMJ, Lowcock J, *et al.* Botulinum toxin for subacute/chronic neck pain. *Cochrane Database Syst Rev* 2011; (7) CD008626. DOI: 10.1002/14651858.pub2.
- [43] Gross AR, Miller J, D'Sylva J, *et al.* COG Manipulation or mobilization for neck pain. *Cochrane Database Syst Rev* 2010; (1) CD004249. DOI: 10.1002/14651858.pub3.
- [44] Higgins JPT, Green S. *Cochrane Handbook for Systematic Review of Interventions* Version 5.0.2 [updated September 2009]. 2008. The Cochrane Collaboration.
- [45] Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. *PLoS Medicine / Public Library of Science* 2009; 6(7): e1000100.
- [46] Tsakitzidis G, Remmen R, Peremans L, *et al.* Non-specific neck pain: diagnosis and treatment. *Good Clinical Practice (GCP) Brussels: KCE Reports 119C* 2009.
- [47] Klippel JH, Stone JH, Crofford LJ, White PH. *Primer on the Rheumatic Diseases*. 13 ed. Atlanta: Springer - Arthritis Foundations 2008.
- [48] Olesen J, for the Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. *Cephalalgia* 2004; 24(1): 9-160.
- [49] Nordin M, Carragee EJ, Hogg-Johnson S, *et al.* Assessment of Neck Pain and Its Associated Disorders. Results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. *J Manipulative Physiol Ther* 2009; 32(2 Suppl): S117-S140.
- [50] Spitzer W, Skovron M, Salmi L, *et al.* Scientific Monograph of the Quebec Task Force on Whiplash-Associated Disorders: Redefining "whiplash" and its management. *Spine* 1995; 20(8S): 1S-73S.
- [51] Kendall MG, Stuart A. *Distribution theory*. 2nd ed. New York: Hafner Publishing Co.; 1963.
- [52] Cicchetti DV. Assessing inter-rater reliability for rating scales: Resolving some basic issues. *Brit J Psychiat* 1976; 129: 452-6.
- [53] Graham N, Haines T, Goldsmith CH, *et al.* Reliability of 3 assessment tools used to evaluate randomized controlled trials for treatment of neck pain. *Spine (Phila Pa 1976)* 2012 Mar 15; 37(6): 515-22.
- [54] Stratford PW, Riddle DL, Binkley JM, Spadoni G, Westaway MD, Padfield B. Using the Neck Disability Index to make decisions concerning individual patients. *Physiother Can* 1999; 2: 107-19.
- [55] Cohen J. *Statistical power analysis for the behavioural sciences*. 2 ed. Hilldale, NJ: Lawrence Erlbaum Associates; 1988.
- [56] Furlan AD, Pennick V, Bombardier C, van Tulder M, Editorial Board CBRG. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. *Spine* 2009 Aug 15; 34(18): 1929-41.
- [57] Altan L, Bingol U, Aykac M, Yurtkuran M. Investigation of the effect of GaAs laser therapy on cervical myofascial pain syndrome. *Rheumatol Int* 2005 Jan; 25(1): 23-7.
- [58] Ceccherelli F, Tortora P, Nassimbeni C, Casale R, Gagliardi G, Giron G. The therapeutic efficacy of somatic acupuncture is not increased by auriculotherapy: A randomised, blind control study in cervical myofascial pain. *Compl Ther Med* 2006; 14(1): 47-52.
- [59] Chow R, Barnsley L, Heller G, Siddall P. A Pilot study of low-level laser therapy in the management of chronic neck pain. *J Musculoskel Pain* 2004; 12(2): 71-81.
- [60] Dunder U, Evcik D, Samli F, Pusak H, Kavuncu V. The effect of gallium arsenide aluminum laser therapy in the management of cervical myofascial pain syndrome: a double blind, placebo-controlled study. *Clin Rheumatol* 2007; 26(6): 930-4.
- [61] Gur A, Sarac AJ, Cevik R, Altindag O, Sarac S. Efficacy of 904 nm gallium arsenide low level laser therapy in the management of chronic myofascial pain in the neck: a double-blind and randomized-controlled trial. *Lasers Surg Med* 2004; 35(3): 229-35.
- [62] Hakguder A, Birtane M, Gurcan S, Kokino S, Turan FN. Efficacy of low level laser therapy in myofascial pain syndrome: an algometric and thermographic evaluation. *Lasers Surg Med* 2003; 33(5): 339-43.
- [63] Ilbuldu E, Cakmak A, Disci R, Aydin R. Comparison of laser, dry needling, and placebo laser treatments in myofascial pain syndrome. *Photomed Laser Surg* 2004; 22(4): 306-11.
- [64] Seidel U, Ulhemann C. Treatment of cervical tendomyositis. Randomized controlled double-blinded study of laser therapy acupuncture and classic acupuncture [translated]. *Deutsche Zeitschrift für Akupunktur* 2002; 2: 258-69.
- [65] Waylonis G, Wilke S, O' Toole D, Waylonis D. Chronic myofascial pain: Management by low-output helium-neon laser therapy. *Arch Phys Med Rehabil* 1988; 69: 1017-20.
- [66] Chow RT, Heller GZ, Barnsley L. The effect of 300 mW, 830 nm laser on chronic neck pain: a double-blind, randomized, placebo-controlled study. *Pain* 2006; 124(1-2): 201-10.
- [67] Soriano FA, Rios R, Pedrola M, Giagnorio J, Battaglioni CR. Acute cervical pain is relieved with gallium-arsenida (GaAs) laser irradiation. A double-blind preliminary study. *Laser Therapy* 1996; 8: 149-54.
- [68] Nilsson N. A randomized controlled trial of the effect of spinal manipulation in the treatment of cervicogenic headache. *J Manipulative Physiol Ther* 1995; 18(7): 435-40.
- [69] Ceccherelli F, Altafini L, Lo Castro G, Avila A, Ambrosio F, Giron GP. Diode laser in cervical myofascial pain: A double-blind study versus placebo. *Clin J Pain* 1989; 5: 301-4.

- [70] Özdemer R, Birtan M, Kokino S. The clinical efficacy of low-power laser therapy on pain and function in cervical osteoarthritis. *Clin Rheumatol* 2001; 20: 181-4.
- [71] Taverna E, Parrini M, Cabitza P. Laser therapy vs placebo in the treatment of some bone and joints pathology. *Minerva Ortop* 1990; 41: 631-66.
- [72] Konstantinovic LM, Cutovic MR, Milovanovic AN, *et al.* Low-level laser therapy for acute neck pain with radiculopathy: a double-blind placebo-controlled randomized study. *Pain Med* 2010; 11(8): 1169-78.
- [73] Yousefi-Nooraie R, Schonstein E, Heidari K, *et al.* Low level laser therapy for nonspecific low-back pain. *Cochrane Database Syst Rev* 2008; (2): CD005107.
- [74] Bjordal JM. Low level laser therapy (LLLT) and World Association for Laser Therapy (WALT) dosage recommendations. *Photomed Laser Surg* 2012; 30(2): 61-2.

Received: October 9, 2012

Revised: October 21, 2012

Accepted: October 26, 2012

© Gross *et al.*; Licensee *Bentham Open*.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.